Safety and tolerability
®
Our data for 749 participants comprising 374 vaccine and 375 placebo recipients demonstrate ETVAX® to have an excellent safety and tolerability profile for travellers. The results accord with a previous study where ETVAX® and the same vaccine without the dmLT or with a higher dose of dmLT adjuvant were administered to a total of 95 Swedish volunteers, 30 receiving the same formulation as used in the present study.